TNFÎ± Cooperates with IFN-Î³ to Repress Bcl-xL Expression to Sensitize Metastatic Colon Carcinoma Cells to TRAIL-mediated Apoptosis
Waller, Jennifer L.
MetadataShow full item record
Background: TNF-related apoptosis-inducing ligand (TRAIL) is an immune effector molecule that functions as a selective anti-tumor agent. However, tumor cells, especially metastatic tumor cells often exhibit a TRAIL-resistant phenotype, which is currently a major impediment in TRAIL therapy. The aim of this study is to investigate the synergistic effect of TNFÎ± and IFN-Î³ in sensitizing metastatic colon carcinoma cells to TRAIL-mediated apoptosis.
Methodology/Principal Findings: The efficacy and underlying molecular mechanism of cooperation between TNFÎ± and IFN-Î³ in sensitizing metastatic colon carcinoma cells to TRAIL-mediated apoptosis were examined. The functional significance of TNFÎ±- and IFN-Î³-producing T lymphocyte immunotherapy in combination with TRAIL therapy in suppression of colon carcinoma metastasis was determined in an experimental metastasis mouse model. We observed that TNFÎ± or IFN-Î³ alone exhibits minimal sensitization effects, but effectively sensitized metastatic colon carcinoma cells to TRAIL-induced apoptosis when used in combination. TNFÎ± and IFN-Î³ cooperate to repress Bcl-xL expression, whereas TNFÎ± represses Survivin expression in the metastatic colon carcinoma cells. Silencing Bcl-xL expression significantly increased the metastatic colon carcinoma cell sensitivity to TRAIL-induced apoptosis. Conversely, overexpression of Bcl-xL significantly decreased the tumor cell sensitivity to TRAIL-induced apoptosis. Furthermore, TNFÎ± and IFN-Î³ also synergistically enhanced TRAIL-induced caspase-8 activation. TNFÎ± and IFN-Î³ was up-regulated in activated primary and tumor-specific T cells. TRAIL was expressed in tumor-infiltrating immune cells in vivo, and in tumor-specific cytotoxic T lymphocytes (CTL) ex vivo. Consequently, TRAIL therapy in combination with TNFÎ±/IFN-Î³-producing CTL adoptive transfer immunotherapy effectively suppressed colon carcinoma metastasis in vivo.
Conclusions/Significance: TNFÎ± and IFN-Î³ cooperate to overcome TRAIL resistance at least partially through enhancing caspase 8 activation and repressing Bcl-xL expression. Combined CTL immunotherapy and TRAIL therapy hold great promise for further development for the treatment of metastatic colorectal cancer.
CitationPLoS One. 2011 Jan 17; 6(1):e16241
- Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
- Authors: El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC
- Issue date: 2011 Aug
- [Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer].
- Authors: Zhu HB, Huang XF, Hu JZ, Zhou W, Chen W, Chen LL, He C
- Issue date: 2008 Apr
- Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.
- Authors: Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K
- Issue date: 2012 May 1
- Bcl-xL/Bax ratio is altered by IFNgamma in TNFalpha- but not in TRAIL-induced apoptosis in colon cancer cell line.
- Authors: Baillat G, Garrouste F, Remacle-Bonnet M, Marvaldi J, Pommier G
- Issue date: 2005 Aug 15
- TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors.
- Authors: Tateishi K, Ohta M, Guleng B, Kanai F, Tanaka Y, Asaoka Y, Jazag A, Imamura J, Imamura T, Ijichi H, Ikenoue T, Kawakami T, Fukushima Y, Washida M, Sata M, Miyagishi M, Taira K, Yoshida H, Kawabe T, Omata M
- Issue date: 2006 May 1